Screening for elevated risk of liver disease in preschool children (Aged 2–5 years) being seen for obesity management

SAGE Open Medicine

Volumn 2, Issue , 2014, Pages

  Beacher, Daniel R ^a,b,c   Ariza, Adolfo J ^b,d,e   Fishbein, Mark H ^d,e   Binns, Helen J ^b,d,e  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Stanley Manne Children's Research Institute   (United States)

^c CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^d CHILDREN'S MEMORIAL HOSPITAL   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alanine aminotransferase; Children; Liver; Nonalcoholic fatty liver disease; Obesity

Indexed keywords

EID: 84962299900     PISSN: None     EISSN: 20503121     Source Type: Journal    
DOI: 10.1177/2050312114555211     Document Type: Article

References (38)

1. Schwimmer JB, Behling C, Newbury R, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42: 641–649.
2. Patton HM, Sirlin C, Behling C, et al. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr 2006; 43: 413–427.
3. Lerret SM and Skelton JA. Pediatric nonalcoholic fatty liver disease. Gastroenterol Nurs 2008; 31: 115–119.
4. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005–2023.
5. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988– 1994. Am J Epidemiol 2013; 178: 38–45.
6. Schwimmer JB, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388– 1393.
7. Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. JAMA 2012; 307: 483–490.
8. Wicklow BA, Wittmeier KD, MacIntosh AC, et al. Metabolic consequences of hepatic steatosis in overweight and obese adolescents. Diabetes Care 2012; 35: 905–910.
9. Manton ND, Lipsett J, Moore DJ, et al. Non-alcoholic steatohepatitis in children and adolescents. Med J Aust 2000; 173: 476–479.
10. Rashid M and Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30: 48–53.
11. August GP, Caprio S, Fennoy I, et al. Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. J Clin Endocrinol Metab 2008; 93: 4576–4599.
12. Barlow SE; Expert Committee. Expert Committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007; 120: S164–S192.
13. Vajro P, Lenta S, Socha P, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 2012; 54: 700–713.
14. Leung DH, Williams K, Fraley JK, et al. Age-and ethnic-spe-cific elevation of ALT among obese children at risk for nonalcoholic steatohepatitis (NASH): implications for screening. Clin Pediatr 2009; 48: 50–57.
15. Estrada E, Eneli I, Hampl S, et al. Children’s Hospital Association consensus statements for comorbidities of childhood obesity. Child Obes 2014; 10: 304–317.
16. Schwimmer JB, Dunn W, Norman GJ, et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 2010; 138: 1357–1364.e2.
17. Welsh JA, Karpen S and Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988–1994 to 2007–2010. J Pediatr 2013; 162: 496–500.e1.
18. Poustchi H, George J, Esmaili S, et al. Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. PLoS One 2011; 6: e21178.
19. Engelmann G, Hoffmann GF, Grulich-Henn J, et al. Alanine aminotransferase elevation in obese infants and children: a marker of early onset non alcoholic fatty liver disease. Hepat Mon 2014; 14: e14112.
20. Calcaterra V, Muratori T, Klersy C, et al. Early-onset metabolic syndrome in prepubertal obese children and the possible role of alanine aminotransferase as marker of metabolic syndrome. Ann Nutr Metab 2011; 58: 307–314.
21. Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008; 48: 119–128.
22. Koot BGP, van der Baan-Slootweg OH, Tamminga-Smeulders CLJ, et al. Lifestyle intervention for non-alcoholic fatty liver disease: prospective cohort study of its efficacy and factors related to improvement. Arch Dis Child 2011; 96: 669–674.
23. Rhee KE, De Lago CW, Arscott-Mills T, et al. Factors associated with parental readiness to make changes for overweight children. Pediatrics 2005; 116: e94–e101.
24. Strauss RS, Barlow SE and Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr 2000; 136: 727–733.
25. Vliet M, Rosenstiel I, Schindhelm R, et al. The association of elevated alanine aminotransferase and the metabolic syndrome in an overweight and obese pediatric population of multi-ethnic origin. Eur J Pediatr 2009; 168: 585–591.
26. Expert Panel on Integrated Guidelines for Cardiovascular Health Risk Reduction in Children and Adolescents. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128: S213–S256.
27. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
28. Kurtoglu S, Hatipoglu N, Mazicioglu M, et al. Insulin resistance in obese children and adolescents: HOMA-IR cut-off levels in the prepubertal and pubertal periods. J Clin Res Pediatr Endocrinol 2010; 2: 100–106.
29. McLaren D and Read W. Classification of nutritional status in early childhood. Lancet 1972; 2: 146–148.
30. DeVore S, Kohli R, Lake K, et al. A multidisciplinary clinical program is effective in stabilizing BMI and reducing transam-inase levels in pediatric patients with NAFLD. J Pediatr Gastroenterol Nutr 2013; 57: 119–123.
31. Wiegand S, Keller KM, Robl M, et al. Obese boys at increased risk for nonalcoholic liver disease: evaluation of 16,390 overweight or obese children and adolescents. Int J Obes 2010; 34: 1468–1474.
32. Schwimmer JB, Celedon MA, Lavine JE, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009; 136: 1585–1592.
33. Sevastianova K, Santos A, Kotronen A, et al. Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. Am J Clin Nutr 2012; 96: 727–734.
34. Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1961–1971.
35. Shashaj B, Bedogni G, Graziani MP, et al. Origin of cardiovascular risk in overweight preschool children: a cohort study of cardiometabolic risk factors at the onset of obesity. JAMA Pediatr. Epub ahead of print 11 August 2014. DOI:10.1001/jamapediatrics.2014.900.
36. Molleston JP, Schwimmer JB, Yates KP, et al. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr 2014; 164: 707–713.e3.
37. Fishbein MH, Miner M, Mogren C, et al. The spectrum of fatty liver in obese children and the relationship of serum ami-notransferases to severity of steatosis. J Pediatr Gastroenterol Nutr 2003; 36: 54–61.
38. Manco M, Alisi A and Nobili V. Risk of severe liver disease in NAFLD with normal ALT levels: a pediatric report. Hepatology 2008; 48: 2087–2088.